<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894710</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL15_0743</org_study_id>
    <secondary_id>2015-005799-90</secondary_id>
    <nct_id>NCT02894710</nct_id>
  </id_info>
  <brief_title>Intravenous Lidocaine in Carcinologic ENT Surgery: A Trial for Evaluation of Opioid Saving Strategy and Chronic Post-surgical Pain (ELICO)</brief_title>
  <acronym>ELICO</acronym>
  <official_title>Intravenous Lidocaine in Carcinologic ENT Surgery: A Randomized Controlled Trial for Evaluation of Opioid Saving Strategy and Chronic Post-surgical Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lidocaine, local anesthetic used for more than five decades, is being intravenously&#xD;
      administered aiming at managing pain in different types of surgeries with promising results.&#xD;
      Opioid-induced hyperalgesia need to be considered in ear-nose-throat (ENT) surgery owing to&#xD;
      the difficulty of locoregional anesthesia and high level of opioid consumption.&#xD;
&#xD;
      This randomized study aims to compare quality of perioperative analgesia after infusion of&#xD;
      intravenous lidocaine during carcinological ENT surgery. The main purpose of this study is to&#xD;
      evaluate morphine consumption during the 48 postoperative hours.&#xD;
&#xD;
      Others purposes are evaluation of peroperative remifentanil consumption, morphine consumption&#xD;
      during the 24 postoperative hours, chronic post-surgical pain evaluated from 3 to 6 months&#xD;
      after carcinologic ENT surgery, and incidence of side effects that can be attributed to&#xD;
      lidocaine infusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine requirement during the first 48 postoperative hours</measure>
    <time_frame>48 postoperative hours (H48)</time_frame>
    <description>Standardized patient control analgesia (PCA) devices will be read at the 48th postoperative hour.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remifentanil peroperative consumption</measure>
    <time_frame>At the end of surgery (an average of 3 hours et 10 minutes)</time_frame>
    <description>from the beginning of anesthesia to end of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total morphine requirement</measure>
    <time_frame>24 postoperative hours (H24)</time_frame>
    <description>Total morphine requirement during the first 24 postoperative hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of chronic post-surgical pain</measure>
    <time_frame>3 to 6 months after surgery (M3-6)</time_frame>
    <description>Chronic post-surgical pain will be evaluated from 3 to 6 month after surgery by a personal interview of each patient with the french version of McGill pain questionnaire (Questionnaire de Saint-Antoine - version abrégée)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects that can be attributed to lidocaine infusion</measure>
    <time_frame>3 to 6 months after surgery (M3-6)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Carcinologic Ear, Nose, and Throat (ENT) Surgery</condition>
  <arm_group>
    <arm_group_label>Lidocaine 20mg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose 5% (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine 20mg/ml</intervention_name>
    <description>Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).</description>
    <arm_group_label>Lidocaine 20mg/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose 5% (placebo)</intervention_name>
    <description>Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.</description>
    <arm_group_label>Glucose 5% (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient undergoing major carcinological ENT surgery (total laryngectomy,&#xD;
             oropharyngectomy with or without mandibulotomy, crico-hyoido-epiglotto-pexy, intraoral&#xD;
             extended resection, partial laryngectomy, partial pharyngectomy, extended pelvectomy,&#xD;
             pelviglossectomy, with or without pectoralis major flap or free flap, with or without&#xD;
             lymphadenectomy)&#xD;
&#xD;
          -  Patient receiving standardized Patient Controlled Analgesia (PCA)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to local anesthetics of the amide group,&#xD;
&#xD;
          -  Acute porphyria&#xD;
&#xD;
          -  Atrioventricular conduction disorders requiring permanent electro-systolic&#xD;
&#xD;
          -  Epilepsy not controlled by treatment&#xD;
&#xD;
          -  Hepatocellular insufficiency (PT&lt;50%) or cirrhosis&#xD;
&#xD;
          -  Systolic heart failure (LVEF &lt;50%)&#xD;
&#xD;
          -  Major inflation State&#xD;
&#xD;
          -  Hypersensitivity to any component of Glucose 5%&#xD;
&#xD;
          -  Treatment with beta-blockers or antiarrhythmic of Vaughan Williams classification&#xD;
&#xD;
          -  BMI &gt; 30kg/m2&#xD;
&#xD;
          -  Patient already treated for chronic pain with level 3 analgesic or for neuropathic&#xD;
             pain&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Refusal to give consent&#xD;
&#xD;
          -  Patient under legal protection measure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospices Civils de Lyon / Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>intravenous lidocaine</keyword>
  <keyword>chronic post-surgical pain</keyword>
  <keyword>remifentanil</keyword>
  <keyword>patient controlled analgesia</keyword>
  <keyword>morphine consumption</keyword>
  <keyword>ENT surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

